Cannabis Cannabinoids And Endocannabinoids

Only a few years ago the endocannabinoid system was unknown. Today we are aware that endocannabinoids are involved in many of the functions of the mammalian body - in neuroprotection, appetite and suckling, pain, reproduction, anxiety, memory, bone formation etc. This volume presents an up-to-date picture of some of the major fields of endocannabinoid research. It summarizes the actions of the endocannabinoids on various physiological systems and opens new therapeutic windows to a large number of diseases. The first chapter, on the use of Cannabis in India, can be viewed as an expression of thanks to the herbal practitioners, who for centuries passed on the medical traditions associated with the drug. The chapter on chemistry is a short summary of active plant, synthetic and endogenous cannabinoids being investigated today, many of which are mentioned later in the book. Cannabidiol is an unusual cannabinoid - it does not bind to the known receptors and yet exerts a variety of effects. Hence a chapter is devoted to it. Further chapters deal with the endocannabinoid system and the endocannabinoids in a variety of conditions and physiological systems. The concluding chapter describes the research done on Sativex®, a standardized plant extract, shortly to be introduced in Canada as a drug for multiple sclerosis. The intended audience is drug researchers (medicinal chemists, pharmacologists, clinicians), neuroscientists, physiologists, and clinicians interested in the effect of the endocannabinoid system in various physiological systems.

Over the past decade, there have been major advances in understanding the mechanisms whereby marijuana interacts with the brain in producing psychoactive and potentially therapeutic effects. The discovery of specific gene coding for cannabinoid receptors activated by smoking marijuana, and the finding of endogenous cannabinoids, which also activate the receptors, have transformed cannabinoid research into mainstream science with significant implications in human health and disease Endocannabinoids: The Brain and Body’s Marijuana and Beyond documentsadvances in the discovery and functioning of naturally occurring marijuana-like substances in human biology. It explores recent findings that point to the existence of an endocannabinoid physiological control system (EPCS) that directly impacts human development, health, and disease. While cannabinoid effects on the brain have received the greatest attention throughout the literature, this work looks at research on the endogenous cannabinoid system’s association across all of human physiology, including the immune, endocrine, and reproductive systems. With thoroughly researched and exceptionally insightful contributions from more than three-dozen top-flight researchers representing a cross-section of disciplines from molecular biology, genetics, and neurology to gynecology, physiology, and pharmacology, this work explores a range of topics as wide as the human body is complex. These topics include the EPCS’s relation to cell development and regulation, CNS function, immune function modulation, reproduction, and digestion, as well as its function in mental illness, neurodegenerative diseases, and cancer. The final section in the book considers the significance of endogenous cannabinoids found in some of the simplest multicellular organisms in the animal kingdom, as well as in mammalian cells at the earliest stages of development, all of which suggests that they play a fundamental role in human biology. Enocannabinoids: The Brain and Body’s Marijuana and Beyond explores areas that few books have ventured into, providing cutting-edge information that will ultimately help us better understand human biology at the systemic and perhaps even cellular level, as well as lead to the development of a whole new range of medications.

'Cannabinoids' is a broad term covering a group of natural products from Cannabis sativa, one of which locks on to specific receptors – protein molecules on the surface of cells – known as cannabinoid receptors. Over the past decades scientists have found that cannabinoid receptors and their endogenous ligands, the endocannabinoids, are involved in a vast array of physiological functions, including helping to control brain activity, energy metabolism, heart function, the immune system and even reproduction. In Cannabinoids, Vincenzo Di Marzo has assembled contributions from international experts to provide the definitive guide to what continues to be a rapidly developing research field. After an introductory historical chapter, the book continues by looking at the biochemical, genetic and molecular elements of cannabinoids, followed by chapters covering their role in health and disease. The final chapter outlines the need for a new nomenclature to reflect the complex and multi-disciplinary nature of this area.

The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy examines the cellular, biochemical, genetic, and therapeutic aspects of the endocannabinoid system. The chapters cover significant conceptual advances in the endocannabinoid field and shed light on the many brain disorders in which this biological system is involved. Written by world-leading experts in the field, the topics covered in this book will have a positive impact on the area of molecular biology, including, but not limited to, cell biology, neuroscience, pharmacology, signaling, disease mechanisms, and therapeutics. Provides an introduction to endocannabinoids in the central nervous system and an overview to their functions in the brain Presents information on neurobiological and cellular studies on the role of the cannabinoid signaling system and its implications in human diseases Includes well-written overviews of the basics of endocannabinoid system structure and function Contains well-illustrated material, with diagrams, charts, and tables Explores compelling case studies and their application to chapters written by experts

Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.

Less than 20 years ago the ?eld of cannabis and the cannabinoids was still c- sidered a minor, somewhat quaint, area of research. A few groups were active in the ?eld, but it was already being viewed as stagnating. The chemistry of cannabis 9 9 was well known, ? -tetrahydrocannabinol (? -THC), identi?ed in 1964, being the only major psychoactive constituent and cannabidiol, which is not psychoactive, possibly contributing to some of the effects. These cannabinoids and several s- thetic analogs had been thoroughly investigated for their pharmacological effects. Their mode of action was considered to be non-speci?c. The reasons for this - sumption were both technical and conceptual. On the technical side, it had been shown that THC was active in both enantiomeric forms (though with a different level of potency) and this observation was incompatible with action on biological substrates—a receptor, an enzyme, an ion channel—which react with a single stereoisomer only. The conceptual problem related to THC activity. This had been pointed out by several highly regarded research groups that had shown that many of the effects seen with cannabinoids were related to those of biologically active lipophiles, and that many of the effects of THC, particularly chronic ones, were comparable to those seen with anaesthetics and solvents.

At the last Annual Representative Meeting of the British Medical Association a motion was passed that `certain additional cannabinoids should be legalized for wider medicinal use.'' This report supports this landmark statement by reviewing the scientific evidence for the therapeutic use of cannabinoids and sets the agenda for change. It will be welcomed by those who believe that cannabinoids can be used in medical treatment. The report discusses in a clear and readable form the use and adverse effects of the drug for nausea, multiple sclerosis, pain, epilepsy, glaucoma, and asthma.

This book presents a well-balanced view of the potential medical use of cannabinoids in pain. It comprehensively covers the current challenges with medical cannabis utilization and provides recommendations for research and future directions. Organized into nine sections, the book begins with an introduction to medical cannabis, including its history, regulations, and the general attitudes of pain physicians on cannabis. Section two explores the biological effects of marijuana via the endocannabinoid system and its complex structure of receptors and enzymes. Sections three, four, and five then delve further into pharmacology and the mechanisms of action applicable to cannabinoids in managing pain. Timely and socially conscious, section six examines the benefits of substituting opioids with cannabinoids for preoperative management. Echoing the book's well-rounded content, sections seven and eight consider the challenges with medical cannabis, including safety and quality control, brain development risks, vaping hazards, and withdrawal. The book then closes with a look at the future of cannabis in medical research. Thoroughly and equitably composed, Cannabinoids and Pain is an invaluable resource for primary care physicians, pain and palliative care physicians, and oncologists.